ArriVent stock plunges 60% after failed clinical trial, shares crater

ArriVent Biopharma's stock collapsed approximately 60% following the failure of a clinical trial for one of its key therapeutic programs. The dramatic decline reflects the high-risk nature of biotech development and investor reassessment of the company's pipeline.

The trial setback removes a major catalyst from the company's near-term prospects, leaving investors focused on remaining development programs and cash runway.